阳离子脂材混合中性胞嘧啶脂材转染3',3''-双肽siRNA缀合物研究

doi:10.5246/jcps.2017.10.081

中国药学(英文版) ›› 2017, Vol. 26 ›› Issue (10): 719-726.DOI: 10.5246/jcps.2017.10.081

阳离子脂材混合中性胞嘧啶脂材转染3',3''-双肽siRNA缀合物研究

杨梦依, 孙晶, 王超, 张艳芬, 张礼和, 杨振军^*

北京大学医学部药学院天然药物及仿生药物国家重点实验室; 药物化学系, 北京 100191

收稿日期:2017-06-10 修回日期:2017-07-15 出版日期:2017-10-31 发布日期:2017-08-20
通讯作者: Tel.: +86-010-82802503, E-mail: yangzj@bjmu.edu.cn
基金资助:
The National Natural Science Foundation of China (Grant No. 21778006 and 20932001), the Ministry of Science and Technology of China (Grant No. 2012AA022501).

Transfection of 3′,3′′-bis-peptide-siRNA conjugate by cationic lipoplexes mixed with a neutral cytosin-1-yl-lipid

Mengyi Yang, Jing Sun, Chao Wang, Yanfen Zhang, Lihe Zhang, Zhenjun Yang^*

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China

Received:2017-06-10 Revised:2017-07-15 Online:2017-10-31 Published:2017-08-20
Contact: Tel.: +86-010-82802503, E-mail: yangzj@bjmu.edu.cn
Supported by:
The National Natural Science Foundation of China (Grant No. 21778006 and 20932001), the Ministry of Science and Technology of China (Grant No. 2012AA022501).

摘要/Abstract

摘要：

阳离子脂质递送siRNA已广泛应用于肿瘤的治疗, 但该类纳米复合物的正电荷堆积可能导致体外和体内严重的细胞毒性和免疫原性, 这限制了基因药物的应用。本研究构建了基于多组分脂质复合物, 递送3′,3′′-双肽-siRNA缀合物(pp-siRNA)用于黑素瘤肿瘤治疗。在阳离子脂材(CLD)包载递送pp-siRNA的基础上, 掺入了一种中性胞嘧啶脂材(DNCA)。当中性材料的比例提高至40%时, 显示了与CLD包载相当的细胞摄取和靶mRNA抑制效果, 同时材料毒性降低, 且纳米复合物主要由巨胞饮和小窝蛋白介导的内吞作用摄取进入A375细胞。此外, 90%的CLD/DNCA pp-siRNA纳米复合物表现出了对突变Braf的mRNA高敲除率(~80%)。结果表明, 混合阳离子脂材CLD及中性脂材DNCA可以实现pp-siRNA的递送和靶基因有效沉默, 在肿瘤治疗方面具有潜在的应用价值。

关键词: 3',3''-双肽-siRNA缀合物, Gemini-like阳离子脂质, 中性胞嘧啶脂材, 黑色素瘤治疗

Abstract:

Cationic lipids have been applied to siRNA delivery for tumor therapeutics. However, the excess positive charges of these nanoplexes may lead to high cytotoxicity and nonnegligible immunogenicity both in vitro and in vivo, which limited the applications of gene drugs. We constructed multi-component lipoplex to delivery 3′,3′′-bis-peptide-siRNA conjugate (pp-siRNA) by the treatment of melanoma. Based on the previous studies that the gemini lipid (CLD) encapsulated pp-siRNA, a novel neutral cytosin-1-yl-lipid (DNCA) was considered to replace a certain ration of CLD by hydrogen bonds and π-π stacking for reducing the cytotoxicity. It similarly retained in both the loading efficiency and targeted mRNA inhibition when DNCA was accounted for 40% in the lipoplex, with lower toxicity. Moreover, CLD/DNCA/pp-siRNA nanoplex could be uptake in A375 cells and internalized mainly by macropinocytosis and caveolin-mediated endocytosis. Besides, 90%CLD/DNCA/pp-siRNA nanoplexes presented the highest efficient knockdown for the mutant B-RAF mRNA (~80%). All the results demonstrated that the mixed cationic and neutral lipids could efficiently realize the delivery of pp-siRNA and had potential application for cancer therapy.

Key words: 3',3''-Bis-peptide siRNA conjugate, Gemini-like cationic lipid, Cytosin-1-yl-lipid, Melanoma therapy

中图分类号:

R916

Supporting:

杨梦依, 孙晶, 王超, 张艳芬, 张礼和, 杨振军. 阳离子脂材混合中性胞嘧啶脂材转染3',3''-双肽siRNA缀合物研究[J]. 中国药学(英文版), 2017, 26(10): 719-726.

Mengyi Yang, Jing Sun, Chao Wang, Yanfen Zhang, Lihe Zhang, Zhenjun Yang. Transfection of 3′,3′′-bis-peptide-siRNA conjugate by cationic lipoplexes mixed with a neutral cytosin-1-yl-lipid[J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(10): 719-726.

参考文献

[1] Shannan, B.; Perego, M.; Somasundaram, R.; Herlyn, M. Cancer. Treat. Res. 2016, 167, 1-15.

[2] Kibbi, N.; Kluger, H.; Choi, J.N. Cancer. Treat. Res. 2016, 167, 107-129.

[3] Chapman, P.B.; Hauschild, A.; Robert, C.; Haanen, J.B.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; Hogg, D.; Lorigan, P.; Lebbe, C.; Jouary, T.; Schadendorf, D.; Ribas, A.; O’Day, S.J.; Sosman, J.A.; Kirkwood, J.M.; Eggermont, A.M.; Dreno, B.; Nolop, K.; Li. J.; Nelson, B.; Hou, J.; Lee, R.J.; Flaherty, K.T.; McArthur, G.A. N. Engl. J. Med. 2011, 364, 2507-2516.

[4] Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M.J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B.A.; Cooper, C.; Shipley, J. Nature. 2002, 417, 949-954.

[5] Castanotto, D.; Rossi, J.J. Nature. 2009, 457, 426-433.

[6] Pecot, C.V.; Calin, G.A.; Coleman, R.L.; Lopez-Berestein, G.; Sood, A.K. Nat. Rev. Cancer. 2011, 11, 59-67.

[7] Scherr, M.; Morgan, M.A.; Eder, M. Curr. Med. Chem. 2003, 10, 245-256.

[8] Whitehead, K.A.; Langer, R.; Anderson, D.G. Nat. Rev. Drug Discov. 2009, 8, 129-138.

[9] David, S.; Pitard, B.; Benoît, J.P.; Passirani, C. Pharmacol. Res. 2010, 62, 100-114.

[10] Liao, W.; Li, W.; Zhang, T.; Kirberger, M.; Liu, J.; Wang, P.; Chen, W.; Wang, Y. Biomater. Sci. 2016, 4, 1051-1061.

[11] Zhang, S.B.; Zhao, B.D.; Jiang, H.M.; Wang, B.; Ma, B.C. J. Controlled Release. 2007, 123, 1-10.

[12] Basha, G.; Novobrantseva, T.I.; Rosin, N.; Tam, Y.Y.; Hafez, I.M.; Wong, M.K.; Sugo, T.; Ruda, V.M.; Qin, J.; Klebanov, B.; Ciufolini, M.; Akinc, A.; Tam, Y.K.; Hope, M.J.; Cullis, P.R. Mol. Ther. 2011, 19, 2186-2200.

[13] Zhang, Y.; Li, H.; Sun, J.; Gao, J.; Liu, W.; Li, B.H.; Guo, Y.J.; Chen, J.M. Int. J. Pharm. 2010, 390, 198-207.

[14] Li, S.D.; Chen, Y.C.; Hackett, M.J. Huang, L. Mol. Ther. 2008, 16, 163-169.

[15] Sarett, S.M.; Werfel, T.A.; Chandra, I.; Jackson, M.A.; Kavanaugh, T.E.; Hattaway, M.E.; Giorgio, T.D.; Duvall, C.L. Biomaterials. 2016, 97, 122-132.

[16] Zheng, Y.; Guo, Y.J.; Li, Y.T.; Wu, Y.; Zhang, L.H.; Yang, Z.J. New J. Chem. 2014, 38, 4952-4962.

[17] Ma, X.F.; Sun, J.; Qiu, C. Wu, Y.F.; Zheng, Y.; Yu, M.Z.; Pei, X.W.; Wei, L.; Niu, Y.J.; Pang, W.H.; Yang, Z.J.; Wang, J.C.; Zhang, Q. J. Controlled Release. 2016, 235, 99-111.

[18] Fan, X.M.; Zhang, Y.F.;, Liu, X.J.; He, H.Y.; Ma, Y.; Sun, J.; Huang, Y.; Wang, X.F.; Wu, Y.; Zhang, L.H.; Yang, Z.J. Bioconjugate Chem. 2016, 27, 1131-1142.

[19] Sun, J.; Qiu, C.; Diao, Y.P.; Wei, W.; Jin, H.W.; Zheng, Y.; Wang, J.C.; Zhang, L.H.; Yang, Z.J. Mol. Ther. Nucleic Acids. 2017, MTNA-17-694.

[20] Campbell, E.M.; Hope, T.J. Gene. Ther. 2005, 12, 1353-1359.

[21] Chan, C.L.; Ewert, K.K.; Majzouba, R.N.; Hwu, Y.K.; Liang, K.S.; Leal, C.; Safinya, C.R. J. Gene. Med. 2014, 16, 84-96.

[22] Simeone, L.; Mangiapia, G.; Irace, C.; Di Pascale, A.; Colonna, A.; Ortona, O.; De Napoli, L.; Montesarchio, D.; Paduano, L. Mol. Biosyst. 2011, 7, 3075-3086.

[23] Cuomo, F.; Ceglie, A.; Lopez, F. J. Colloid. Interf. Sci. 2012, 365, 184-190.
[24] Milani, S.; Bombelli, F.B.; Berti, D.; Baglioni, P. J. Am. Chem. Soc. 2007, 129, 11664-11665.

阳离子脂材混合中性胞嘧啶脂材转染3',3''-双肽siRNA缀合物研究

Transfection of 3′,3′′-bis-peptide-siRNA conjugate by cationic lipoplexes mixed with a neutral cytosin-1-yl-lipid

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李明娜, 吴兴, 张亮仁, 刘振明. 反向对接的选择性与非选择性抑制剂找靶评价: Glide个案研究[J]. 中国药学(英文版), 2020, 29(10): 679-688.
[2]	焦佩丽, 李奕言, 吴兴, 王昱曦, 毛蓓蓓, 金宏威, 张礼和, 张亮仁, 刘振明. 基于结构设计的新型mTOR抑制剂的抗宫颈癌活性研究[J]. 中国药学(英文版), 2020, 29(9): 603-616.
[3]	刘慧, 梁磊, 袁兰, 许凤荣, 牛彦, 王超, 徐萍. 氮杂芳香环并哒嗪酮类荧光探针的设计、合成和生物成像的应用[J]. 中国药学(英文版), 2019, 28(5): 298-315.
[4]	周北斗, 王欣, 翁智敏, 黄堡城, 马泽通, 于博, 阮丽琴, 胡栋宝. 氧杂蒽酮的合成和抗肿瘤、抑制酪氨酸酶和抑制血小板聚集活性研究[J]. 中国药学(英文版), 2019, 28(4): 247-256.
[5]	王新童, 邹文星, 肖浩然, 谢文军, 李鑫, 卞希玲, 孙崎, 王克威. 呋喃并[3,2-b]吡啶类化合物对α7尼古丁乙酰胆碱受体负向变构调节作用的电生理学评价[J]. 中国药学(英文版), 2019, 28(3): 160-166.
[6]	贺明, 谢宝花, 贺培, 周海兵, 黄胜堂, 董春娥. 喹啉-苯并吡喃类新型乙酰胆碱酯酶抑制剂的微波一锅法的设计合成以及生物活性研究[J]. 中国药学(英文版), 2018, 27(11): 735-752.
[7]	Olatunde S. Oladeji, Monisola I. Ikhile, Carine M. D. Fotsing, Messai Mamo, Patrick G. Ndungu, Derek T. Ndinteh. Synthesis of 4-aminoantipyrine Schiff bases and their antimicrobial activities[J]. 中国药学(英文版), 2018, 27(11): 753-766.
[8]	李灿, 李宏月, 孙静, 席丹丹, 王超, 梁磊, 许凤荣, 牛彦, 徐萍. 5-苄基-2-苯基嘧啶-4(3H)-酮类新型MEK抑制剂基于结构的设计与合成[J]. 中国药学(英文版), 2018, 27(10): 686-695.
[9]	Dini Kesuma, Siswandono, Bambang Tri Purwanto, Marcellino Rudyanto. Synthesis of N-(phenylcarbamothioyl)-benzamide derivatives and their cytotoxic activity against MCF-7 cells[J]. 中国药学(英文版), 2018, 27(10): 696-702.
[10]	马玉翠, 徐靓, 吴翠, 巢志茂. 反式-3-苯基-2-丙烯酸的晶体结构[J]. 中国药学(英文版), 2018, 27(9): 644-648.
[11]	黄宗泽, 王新童, 孟盈, 李鑫, 肖浩然, 卞希玲, 王克威, 孙崎. 3H-喹唑啉-4-酮衍生物的设计、合成及其α7尼古丁乙酰胆碱受体正向变构调节作用评价[J]. 中国药学(英文版), 2018, 27(8): 540-552.
[12]	黄慧霞, 刘会雪, 马孝杰, 管辉, 杨晓改. 氯化镧和柠檬酸镧在胃肠道以磷酸镧微粒为转化物种且主要通过M细胞进行转运吸收[J]. 中国药学(英文版), 2018, 27(8): 553-564.
[13]	李亦博, 周鑫, 刘振明, 张亮仁. 基于深度分子生成模型的类天然产物虚拟筛选库设计[J]. 中国药学(英文版), 2018, 27(7): 451-459.
[14]	孟盈, 邹文星, 黄宗泽, 王新童, 焦文宣, 谢文军, 卞希玲, 王克威, 孙崎. 无配体钯催化的Suzuki羰基化反应研究及其在α7 nAChR 正向变构调节剂改造中的应用[J]. 中国药学(英文版), 2018, 27(7): 460-468.
[15]	刘芸奇, 李茜茜, 豆晓东, 田超, 张志丽, 刘俊义, 王孝伟. 相似的吡啶酮类化合物具有显著不同的抗HIV-1 逆转录酶活性[J]. 中国药学(英文版), 2018, 27(7): 469-477.